<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369680</url>
  </required_header>
  <id_info>
    <org_study_id>KETA-2011</org_study_id>
    <nct_id>NCT01369680</nct_id>
  </id_info>
  <brief_title>Oral Ketamine for Control of Chronic Pain in Children</brief_title>
  <acronym>KETA-2011</acronym>
  <official_title>Oral Ketamine for Control of Chronic Pain in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a maximum tolerated dose finding study for oral, chronic, daily administration
      of oral ketamine (by mouth) in children with long-term daily pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain control in children is a major concern when children have chronic diseases, such as
      cancer and sickle cell disease with frequent pain crises. Additionally, though the
      traditional pain medications of morphine and acetaminophen are regarded as safe and effective
      for pain control in children, there are few alternative therapies available when these
      medications are insufficient. Chronic pain (whether cancer or non-cancer pain) in children
      has few approved and well tolerated therapeutic options with proven efficacy.

      Ketamine is a medication that was first described in 1962[1]. It is an NMDA-R
      (N-methyl-D-aspartate-receptor) antagonist with dissociative amnestic and analgesic
      effects[1-2]. Ketamine is particularly successful as a dissociative amnestic for children in
      the emergent setting as it has little respiratory or cardiac impact, has a short half-life,
      and has fewer psychomimetic effects in the pediatric population than in adults[1]. Its
      function is via antagonism and reduction of NMDA-receptors in the afferent pain pathway. In
      effect, this decreases pain receptors and can dramatically reduce the need for narcotic pain
      medications for patients with chronic pain.

      Unfortunately, with such dissociative effects, ketamine has been a drug of abuse for
      decades[1,3]. Additionally, there is concern that ketamine may have long-term deleterious
      effects on cognition for those subjects chronically exposed to IV ketamine[4], especially
      children whose neural pathways may still be developing[1,5]. These effects may include
      difficulty with attention and working memory, though the effects appear to be short-term and
      reversible in adults. However, much of this data is derived from rodent or primate studies,
      and there is little evidence that there are long-term cognitive effects on humans chronically
      exposed to ketamine[1]. This lack of data is particularly impactful in the pediatric group.

      Ketamine has been evaluated as an analgesic medication for patients with chronic pain that is
      not resolved with narcotics and gabapentin. There are a number of case reports and small case
      series that suggest ketamine is a useful medication for control of chronic pain in
      adults[2,4,6-8]. Additionally, there are case studies that describe lasting (12 week) pain
      control in adults after 4-10 days of ketamine therapy[7-8]. However, there are, to date,
      little data that aid a pediatrician in determining if ketamine is a safe and effective option
      as a chronic, oral therapy for children with chronic pain.

      Overall, there are few proven safe and effective medications for use in chronic pain
      management for children. Ketamine is a well known medication with a well elaborated safety
      profile, when given intravenously and for short periods of time. There is, as above, emerging
      data that ketamine is useful for chronic pain control in adults. The question that remains to
      be answered is whether ketamine is a safe option for chronic use in children, whose brains
      are significantly more plastic and whose metabolism is different compared with those of
      adults.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Tolerating Dose</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Effect</measure>
    <time_frame>At 14 weeks</time_frame>
    <description>Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.
The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norketamine Cmax (Measured in ng/mL).</measure>
    <time_frame>At week 1</time_frame>
    <description>Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Control</measure>
    <time_frame>Week 2</time_frame>
    <description>Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.
Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Ketamine 0.25 mg/kg/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first three subjects were administered 0.25 mg/kg/dose oral ketamine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.5 mg/kg/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The second group of three subjects were administered 0.5 mg/kg/dose oral ketamine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 1 mg/kg/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The third group of three subjects were administered 1 mg/kg/dose oral ketamine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 1.5 mg/kg/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The fourth group of three subjects were administered 1.5 mg/kg/dose oral ketamine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.</description>
    <arm_group_label>Ketamine 0.25 mg/kg/dose</arm_group_label>
    <arm_group_label>Ketamine 0.5 mg/kg/dose</arm_group_label>
    <arm_group_label>Ketamine 1 mg/kg/dose</arm_group_label>
    <arm_group_label>Ketamine 1.5 mg/kg/dose</arm_group_label>
    <other_name>Ketalar</other_name>
    <other_name>Ketamine hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject, parent, or guardian willing and able to give informed consent

          -  NRS for pain &gt;4

          -  Chronic pain, which has been present for &gt;3 months, or persisting longer than is
             normal for the underlying diagnosis

          -  Chronic pain related to diagnoses including but not limited to: cancer, rheumatologic
             disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease
             (e.g. Duchenne muscular dystrophy)

          -  Able to tolerate and cooperate with neurocognitive assessment

          -  Age 8-22 years old

        Exclusion Criteria:

          -  If they are known or suspected to have drug dependence or addiction

          -  History of psychiatric disorder such as depression, schizophrenia, or bipolar disorder

          -  History of hypertension

          -  Unable to cooperate with neurocognitive assessment

          -  Chronic pain related to chronic abdominal pain syndrome

          -  Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of
             normal.

          -  Previous intolerance or allergic reaction to ketamine

          -  Pregnancy

          -  Use of CYP3A4 inhibitors or inducers within the 2 week period prior the study drug
             administration or within 5 half-lives of the respective medication, whichever is
             longer, until study conclusion.

          -  Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study
             drug administration until study conclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Korones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Green SM, Cot√© CJ. Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. Ann Emerg Med. 2009 Aug;54(2):181-90. doi: 10.1016/j.annemergmed.2008.10.003. Epub 2008 Nov 6. Review.</citation>
    <PMID>18990467</PMID>
  </reference>
  <reference>
    <citation>Okon T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician. 2007 May;10(3):493-500. Review.</citation>
    <PMID>17525784</PMID>
  </reference>
  <reference>
    <citation>Kronenberg RH. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J Pain Palliat Care Pharmacother. 2002;16(3):27-35. Review.</citation>
    <PMID>14640353</PMID>
  </reference>
  <reference>
    <citation>Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 2006 Aug;60(7):341-8. Epub 2006 Jul 5. Review.</citation>
    <PMID>16854557</PMID>
  </reference>
  <reference>
    <citation>Wilder RT, Flick RP, Sprung J, Katusic SK, Barbaresi WJ, Mickelson C, Gleich SJ, Schroeder DR, Weaver AL, Warner DO. Early exposure to anesthesia and learning disabilities in a population-based birth cohort. Anesthesiology. 2009 Apr;110(4):796-804. doi: 10.1097/01.anes.0000344728.34332.5d.</citation>
    <PMID>19293700</PMID>
  </reference>
  <reference>
    <citation>Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009 Dec 15;147(1-3):107-15. doi: 10.1016/j.pain.2009.08.015. Epub 2009 Sep 23.</citation>
    <PMID>19783371</PMID>
  </reference>
  <reference>
    <citation>Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, Dahan A. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain. 2009 Oct;145(3):304-11. doi: 10.1016/j.pain.2009.06.023. Epub 2009 Jul 14.</citation>
    <PMID>19604642</PMID>
  </reference>
  <reference>
    <citation>Bell RF. Ketamine for chronic non-cancer pain. Pain. 2009 Feb;141(3):210-4. doi: 10.1016/j.pain.2008.12.003. Epub 2009 Jan 6. Review.</citation>
    <PMID>19128879</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <results_first_submitted>October 24, 2012</results_first_submitted>
  <results_first_submitted_qc>February 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2013</results_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>David Korones</investigator_full_name>
    <investigator_title>Director, Pediatric Palliative Care</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Chronic pain</keyword>
  <keyword>Children</keyword>
  <keyword>Oral pain medication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began in June 2011 and closed in April 2012. Patients were referred by their primary pain physician.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine 0.25 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 0.25 mg/kg/dose oral ketamine.</description>
        </group>
        <group group_id="P2">
          <title>Ketamine 0.5 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 0.5 mg/kg/dose oral ketamine.</description>
        </group>
        <group group_id="P3">
          <title>Ketamine 1 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 1 mg/kg/dose oral ketamine.</description>
        </group>
        <group group_id="P4">
          <title>Ketamine 1.5 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 1.5 mg/kg/dose oral ketamine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine 0.25 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 0.25 mg/kg/dose oral ketamine.</description>
        </group>
        <group group_id="B2">
          <title>Ketamine 0.5 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 0.5 mg/kg/dose oral ketamine.</description>
        </group>
        <group group_id="B3">
          <title>Ketamine 1 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 1 mg/kg/dose oral ketamine.</description>
        </group>
        <group group_id="B4">
          <title>Ketamine 1.5 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 1.5 mg/kg/dose oral ketamine.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Tolerating Dose</title>
        <description>According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity.</description>
        <time_frame>Up to 2 weeks</time_frame>
        <population>Number of participants was determined through negotiation with the FDA for safety of all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.25 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 0.25 mg/kg/dose oral ketamine</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.5 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 0.5 mg/kg/dose oral ketamine</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 1 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 1 mg/kg/dose oral ketamine</description>
          </group>
          <group group_id="O4">
            <title>Ketamine 1.5 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 1.5 mg/kg/dose oral ketamine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Tolerating Dose</title>
          <description>According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity.</description>
          <population>Number of participants was determined through negotiation with the FDA for safety of all participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Effect</title>
        <description>Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.
The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores.</description>
        <time_frame>At 14 weeks</time_frame>
        <population>All participants not lost to follow-up were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.25 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 0.25 mg/kg/dose oral ketamine. Measure was for clinically significant decline in neurocognitive scores.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.5 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 0.5 mg/kg/dose oral ketamine. Measure was for clinically significant decline in neurocognitive scores.</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 1 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 1 mg/kg/dose oral ketamine. Measure was for clinically significant decline in neurocognitive scores.</description>
          </group>
          <group group_id="O4">
            <title>Ketamine 1.5 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 1.5 mg/kg/dose oral ketamine. Measure was for clinically significant decline in neurocognitive scores.</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Effect</title>
          <description>Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.
The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores.</description>
          <population>All participants not lost to follow-up were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Norketamine Cmax (Measured in ng/mL).</title>
        <description>Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children.</description>
        <time_frame>At week 1</time_frame>
        <population>All participants consenting for pharmacokinetics were analyzed. No participants in ketamine 1.5 mg/kg/dose group consented for pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.25 mg/kg/Dose</title>
            <description>Subjects treated at 0.25 mg/kg/dose consenting for separate pharmacokinetics test at week 1 of study.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.5 mg/kg/Dose</title>
            <description>Subjects treated at 0.5 mg/kg/dose consenting for separate pharmacokinetics test at week 1 of study.</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 1 mg/kg/Dose</title>
            <description>Subjects treated at 1 mg/kg/dose consenting for separate pharmacokinetics test at week 1 of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Norketamine Cmax (Measured in ng/mL).</title>
          <description>Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children.</description>
          <population>All participants consenting for pharmacokinetics were analyzed. No participants in ketamine 1.5 mg/kg/dose group consented for pharmacokinetics.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="20" upper_limit="55"/>
                    <measurement group_id="O2" value="135" lower_limit="120" upper_limit="150"/>
                    <measurement group_id="O3" value="250" lower_limit="250" upper_limit="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Control</title>
        <description>Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.
Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain.</description>
        <time_frame>Week 2</time_frame>
        <population>Number of participants for analysis was determined in negotiation with the FDA for safety of all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.25 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 0.25 mg/kg/dose oral ketamine.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.5 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 0.5 mg/kg/dose oral ketamine.</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 1 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 0.25 mg/kg/dose oral ketamine.</description>
          </group>
          <group group_id="O4">
            <title>Ketamine 1.5 mg/kg/Dose</title>
            <description>Cohort of three subjects administered 1.5 mg/kg/dose oral ketamine.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Control</title>
          <description>Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.
Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain.</description>
          <population>Number of participants for analysis was determined in negotiation with the FDA for safety of all participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine 0.25 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 0.25 mg/kg/dose oral ketamine.</description>
        </group>
        <group group_id="E2">
          <title>Ketamine 0.5 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 0.5 mg/kg/dose oral ketamine.</description>
        </group>
        <group group_id="E3">
          <title>Ketamine 1 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 1 mg/kg/dose oral ketamine.</description>
        </group>
        <group group_id="E4">
          <title>Ketamine 1.5 mg/kg/Dose</title>
          <description>Cohort of three participants treated at 1.5 mg/kg/dose oral ketamine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Multiple infections in one subject with complex medical diagnoses. Not thought to be related to study drug.</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <description>Withdrawal from chronic opioid therapy.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Relieved with defecation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Three subjects were lost to follow-up, limiting the data available for neuro-cognitive assessment at the last visit.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Amy-Lee Bredlau</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-2957 ext 62872</phone>
      <email>bredlau@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

